Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1991-6-24
|
pubmed:abstractText |
Our study had three purposes: 1) to determine whether 5-methyl-urapidil, topically applied to the ventrolateral medulla, produces hypotension by activating serotonin-1A (5-HT1A) receptors, 2) to determine whether 5-methyl-urapidil given i.v. produces hypotension in part by activating 5-HT1A receptors in the ventrolateral medulla, and 3) to determine the specific site within the ventrolateral medulla where 5-methyl-urapidil elicits a hypotensive response. In terms of the first purpose, 5-methyl-urapidil applied bilaterally to the intermediate area of the ventral surface of the medulla (1.2 micrograms/side) of chloralose-anesthetized cats produced a decrease in mean arterial pressure of -39 +/- 4 mm Hg (N = 8). Prior blockade of 5-HT1A receptors at this site with bilateral application of spiperone (30 micrograms/side) prevented the hypotensive effect of 5-methyl-urapidil (mean blood pressure now increased by 5 +/- 4 mm Hg). Pretreatment with the alpha-1 adrenoceptor antagonist, prazosin, did not prevent the hypotensive effect of 5-methyl-urapidil. In terms of the second purpose, spiperone applied bilaterally to the ventral surface of the medulla counteracted a significant portion of the hypotensive effect of 5-methyl-urapidil given by the i.v. route. The dose of 5-methyl-urapidil given intravenously was below the dose that produces alpha-1 adrenoceptor blockade. In terms of the third purpose, microinjection of 5-methyl-urapidil into central nervous system sites associated with the intermediate area was found to have its greatest hypotensive effect at the subretrofacial nucleus. Mean arterial pressure decreased by 74 +/- 14 mm Hg (N = 3) after bilateral microinjection of 25 ng of the drug.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/5-methylurapidil,
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic alpha-Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Serotonin,
http://linkedlifedata.com/resource/pubmed/chemical/Spiperone
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0022-3565
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
257
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
861-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1674536-Administration, Topical,
pubmed-meshheading:1674536-Adrenergic alpha-Antagonists,
pubmed-meshheading:1674536-Animals,
pubmed-meshheading:1674536-Blood Pressure,
pubmed-meshheading:1674536-Cats,
pubmed-meshheading:1674536-Dose-Response Relationship, Drug,
pubmed-meshheading:1674536-Drug Interactions,
pubmed-meshheading:1674536-Female,
pubmed-meshheading:1674536-Heart Rate,
pubmed-meshheading:1674536-Hypotension,
pubmed-meshheading:1674536-Injections, Intravenous,
pubmed-meshheading:1674536-Male,
pubmed-meshheading:1674536-Medulla Oblongata,
pubmed-meshheading:1674536-Microinjections,
pubmed-meshheading:1674536-Piperazines,
pubmed-meshheading:1674536-Receptors, Serotonin,
pubmed-meshheading:1674536-Spiperone
|
pubmed:year |
1991
|
pubmed:articleTitle |
The role of serotonin-1A receptor activation and alpha-1 adrenoceptor blockade in the hypotensive effect of 5-methyl-urapidil.
|
pubmed:affiliation |
Department of Pharmacology, Georgetown University School of Medicine, Washington, D.C.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|